Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer.
Adjuvant treatment
Breast cancer
Concurrent
Human epidermal growth-factor receptor 2
Sequential
Trastuzumab
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
11
05
2020
accepted:
09
10
2020
pubmed:
29
10
2020
medline:
24
6
2021
entrez:
28
10
2020
Statut:
ppublish
Résumé
The addition of trastuzumab to adjuvant chemotherapy has improved the outcome of human epidermal growth-factor receptor 2 (HER2)-positive breast cancer. Uncertainty remains about the optimal timing of trastuzumab treatment. Therefore, we compared long-term outcome after concurrent versus sequential treatment, in a population-based setting, using data from the nationwide Netherlands Cancer Registry. We identified 1843 women diagnosed in The Netherlands from January 1st 2005 until January 1st 2008 with primary, HER2-positive, T After a median follow-up of 8.2 years, RFS events had occurred in 224 out of 1235 (18.1%) concurrently treated women and 129 out of 608 (21.2%) sequentially treated women (adjusted-HR 0.91; 95% confidence interval (CI) 0.67-1.24; P = 0.580). Deaths occurred in 182/1235 (14.7%) concurrently treated women and 104/608 (17.1%) sequentially treated women (adjusted-HR 0.92; 95% CI 0.65-1.29; P = 0.635). The results of this population-based study are consistent with earlier randomized trials, demonstrating a non-significant difference in outcome for concurrently treated women compared to those who were treated sequentially, suggesting both options are justified.
Identifiants
pubmed: 33113088
doi: 10.1007/s10549-020-05978-8
pii: 10.1007/s10549-020-05978-8
pmc: PMC7921067
doi:
Substances chimiques
Receptor, ErbB-2
EC 2.7.10.1
Trastuzumab
P188ANX8CK
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
817-830Subventions
Organisme : ZonMw
ID : 836021019
Références
J Clin Oncol. 2007 May 20;25(15):2127-32
pubmed: 17513820
Appl Immunohistochem Mol Morphol. 2011 Dec;19(6):499-500
pubmed: 22089488
J Clin Oncol. 2014 Nov 20;32(33):3744-52
pubmed: 25332249
J Natl Compr Canc Netw. 2009 Feb;7(2):122-92
pubmed: 19200416
Lancet Oncol. 2018 Dec;19(12):1630-1640
pubmed: 30413379
J Clin Oncol. 2007 Jan 1;25(1):118-45
pubmed: 17159189
Ann Oncol. 2019 Aug 1;30(8):1194-1220
pubmed: 31161190
N Engl J Med. 1994 May 5;330(18):1260-6
pubmed: 7908410
J Clin Oncol. 2003 Mar 15;21(6):976-83
pubmed: 12637460
Eur J Cancer. 2010 Sep;46(14):2633-46
pubmed: 20843492
J Clin Oncol. 2011 Dec 1;29(34):4491-7
pubmed: 22042958
J Natl Cancer Inst. 2008 Jan 2;100(1):14-20
pubmed: 18159072
Lancet Oncol. 2011 Mar;12(3):236-44
pubmed: 21354370
J Clin Oncol. 2009 Dec 20;27(36):6129-34
pubmed: 19917839
J Clin Oncol. 2018 Jul 10;36(20):2105-2122
pubmed: 29846122
N Engl J Med. 2015 Jan 8;372(2):134-41
pubmed: 25564897
Lancet. 2007 Jan 6;369(9555):29-36
pubmed: 17208639
Eur J Cancer. 2017 Aug;81:151-160
pubmed: 28624696
N Engl J Med. 2008 Apr 17;358(16):1663-71
pubmed: 18420499
J Clin Oncol. 2016 Apr 1;34(10):1034-42
pubmed: 26598744
Eur J Cancer. 2017 Mar;74:47-54
pubmed: 28335887
J Natl Cancer Inst. 2002 Jun 5;94(11):852-4
pubmed: 12048273
N Engl J Med. 2005 Oct 20;353(16):1659-72
pubmed: 16236737
N Engl J Med. 2001 Mar 15;344(11):783-92
pubmed: 11248153
N Engl J Med. 2005 Oct 20;353(16):1673-84
pubmed: 16236738
N Engl J Med. 2011 Oct 6;365(14):1273-83
pubmed: 21991949